Portal de Periódicos da CAPES

Pharmacogenetics and statin-related myopathy: what do we know?

2020; Future Medicine; Volume: 21; Issue: 12 Linguagem: Inglês

10.2217/pgs-2020-0041

1744-8042

Richard M. Turner, Ivana Radman, Nada Božina, Ana Alfirevic,

Protein Kinase Regulation and GTPase Signaling

PharmacogenomicsVol. 21, No. 12 EditorialPharmacogenetics and statin-related myopathy: what do we know?Richard Myles Turner, Ivana Radman, Nada Bozina & Ana AlfirevicRichard Myles TurnerDepartment of Molecular & Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Block A, Waterhouse Building, 1–5 Brownlow Street, Liverpool, L69 3GL, UK, Ivana RadmanUniversity Department of Ophthalmology, University Hospital Centre Sestre milosrdnice, Vinogradska cesta, 10000 Zagreb, Croatia, Nada BozinaDepartment of Pharmacology, School of Medicine, University of Zagreb, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia & Ana Alfirevic *Author for correspondence: Tel.: +44 151 794 5551; E-mail Address: ana.alfirevic@liverpool.ac.ukhttps://orcid.org/0000-0002-2801-9817Department of Molecular & Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Block A, Waterhouse Building, 1–5 Brownlow Street, Liverpool, L69 3GL, UKPublished Online:29 Jul 2020https://doi.org/10.2217/pgs-2020-0041AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: adverse drug reactiondrug-induced muscle injurymyopathyrhabdomyolysisSLCO1B1statinReferences1. Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670–1681 (2010).Crossref, Medline, Google Scholar2. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA 316(19), 2008–2024 (2016).Crossref, Medline, Google Scholar3. Azemawah V, Movahed MR, Centuori P et al. State of the art comprehensive review of individual statins, their differences, pharmacology, and clinical implications. Cardiovasc. Drugs Ther. 33(5), 625–639 (2019).Crossref, Medline, CAS, Google Scholar4. Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J. Clin. Med. 9(1), 22–59 (2019).Crossref, Google Scholar5. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am. J. Med. 125(9), 882–887 e881 (2012).Crossref, Medline, Google Scholar6. de Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br. J. Clin. Pharmacol. 78(4), 684–698 (2014).Crossref, Medline, CAS, Google Scholar7. Alfirevic A, Neely D, Armitage J et al. Phenotype standardization for statin-induced myotoxicity. Clin. Pharmacol. Ther. 96(4), 470–476 (2014).Crossref, Medline, CAS, Google Scholar8. Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J. Clin. Lipidol. 7(5), 472–483 (2013).Crossref, Medline, Google Scholar9. Parker BA, Capizzi JA, Grimaldi AS et al. Effect of statins on skeletal muscle function. Circulation 127(1), 96–103 (2013).Crossref, Medline, CAS, Google Scholar10. Nissen SE, Stroes E, Dent-Acosta RE et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 315(15), 1580–1590 (2016).Crossref, Medline, CAS, Google Scholar11. Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 238(2), 329–335 (2015).Crossref, Medline, CAS, Google Scholar12. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med. 359(8), 789–799 (2008).Crossref, Medline, CAS, Google Scholar13. de Keyser CE, Peters BJ, Becker ML et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet. Genomics 24(1), 43–51 (2014).Crossref, Medline, CAS, Google Scholar14. Donnelly LA, Doney AS, Tavendale R et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with Type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther. 89(2), 210–216 (2011).Crossref, Medline, CAS, Google Scholar15. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16(12), 873–879 (2006).Crossref, Medline, CAS, Google Scholar16. Postmus I, Trompet S, Deshmukh HA et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat. Commun. 5, 5068 (2014).Crossref, Medline, CAS, Google Scholar17. Carr DF, Francis B, Jorgensen AL et al. Genome-wide association study of statin-induced myopathy in patients recruited using the UK clinical practice research datalink. Clin. Pharmacol. Ther. 106(6), 1353–1361 (2019).Crossref, Medline, CAS, Google Scholar18. Marciante KD, Durda JP, Heckbert SR et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet. Genomics 21(5), 280–288 (2011).Crossref, Medline, CAS, Google Scholar19. Santos PC, Soares RA, Nascimento RM et al. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: amerindians as a high risk ethnic group. BMC Med. Genet. 12, 136 (2011).Crossref, Medline, CAS, Google Scholar20. Dong OM, Wheeler SB, Cruden G et al. Cost–effectiveness of multigene pharmacogenetic testing in patients with acute coronary syndrome after percutaneous coronary intervention. Value Health 23(1), 61–73 (2020).Crossref, Medline, Google Scholar21. Elam MB, Majumdar G, Mozhui K et al. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS ONE 12(8), e0181308 (2017).Crossref, Medline, Google Scholar22. Ferrari M, Guasti L, Maresca A et al. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur. J. Clin. Pharmacol. 70(5), 539–547 (2014).Crossref, Medline, CAS, Google Scholar23. Floyd JS, Bloch KM, Brody JA et al. Pharmacogenomics of statin-related myopathy: meta-analysis of rare variants from whole-exome sequencing. PLoS ONE 14(6), e0218115 (2019).Crossref, Medline, CAS, Google Scholar24. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 38(32), 2459–2472 (2017).Crossref, Medline, CAS, Google Scholar25. Khera AV, Chaffin M, Aragam KG et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50(9), 1219–1224 (2018).Crossref, Medline, CAS, Google Scholar26. Budoff MJ, Young R, Burke G et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur. Heart J. 39(25), 2401–2408 (2018).Crossref, Medline, CAS, Google Scholar27. Tatham LM, Liptrott NJ, Rannard SP, Owen A. Long-acting injectable statins-is it time for a paradigm shift?. Molecules 24(15), 2685 (2019).Crossref, Google ScholarFiguresReferencesRelatedDetailsCited ByABCG2 and SLCO1B1 gene polymorphisms in the Croatian population9 December 2022 | Annals of Human Biology, Vol. 49, No. 7-8An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice25 April 2022 | Frontiers in Pharmacology, Vol. 13Drug-induced Myopathies28 July 2021 | Zeitschrift für Orthopädie und Unfallchirurgie, Vol. 80Pharmacogenomics of statins and familial hypercholesterolemia11 February 2021 | Current Opinion in Lipidology, Vol. 32, No. 2 Vol. 21, No. 12 Follow us on social media for the latest updates Metrics Downloaded 213 times History Received 26 March 2020 Accepted 26 March 2020 Published online 29 July 2020 Published in print August 2020 Information© 2020 Future Medicine LtdKeywordsadverse drug reactiondrug-induced muscle injurymyopathyrhabdomyolysisSLCO1B1statinFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download